Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results
Yıl: 2011 Cilt: 19 Sayı: 2 Sayfa Aralığı: 97 - 102 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results
Öz: Amaç: Neovasküler yaşa bağlı maküla dejenerasyonunda (YBMD), tek başına intravitreal bevacizumab enjeksiyonu (İVB) ile fotodinamik tedavi (FDT) ve İVB kombinasyon tedavisinin anatomik ve görsel sonuçlarının değerlendirilmesi. Gereç ve Yöntem: Bu geriye dönük çalışmaya daha önce tedavi almamış neovasküler YBMD’li gözler dahil edildi. Çalışma tek başına İVB tedavisi alan 1. grup ve İVB+FDT tedavisi alan 2. grup olmak üzere toplam 2 gruptan oluşturuldu. Tedavi öncesi ve sonrası tüm kontrollerde her lezyona bir aktivite skoru (AS) verildi. Parametrelerin karşılaştırılmasında Student’s t testi ve Ki-kare testi kullanıldı.Bulgular: Çalışmaya toplam 53 göz dahil edildi. Ortalama takip süresi 12.3 ay idi. Tedavi öncesinde gruplar arasında lezyon tipi, görme keskinliği ve santral foveal kalınlık açısında bir fark izlenmedi. Tedavi sonrasında AS her iki grupta da anlamlı olarak azaldı (p<0.05). Görme keskinliği 1. gruptaki gözlerin %92.5’inde aynı veya artmış olarak izlenirken bu oran 2.grupta %88.5 idi (p>0.05). Ortalama İVB/göz sayısı 1. grupta 2.7, 2. grupta ise 2.6 olarak hesaplandı (p>0.05).Sonuç: İVB+FDT kombinasyon tedavisi tek başına İVB tedavisine göre, görme keskinliği ve tekrar tedavi ihtiyacı açısından üstün görünmemektedir. Tekrar tedavi ihtiyacının belirlenmesinde aktivite skorlama sisteminin kullanılması yardımcı olabilir.
Anahtar Kelime: Konular:
Yaşa bağlı maküla dejenerasyonuna bağlı koroidal neovaskülarizasyon tedavisinde tek başına bevacizumab veya fotodinamik tedavi ile kombinasyon: 12 ay sonuçları
Öz: Purpose: To determine the anatomical and visual responses to intravitreal bevacizumab injection (IVB) monotherapy and the combination of IVB with photodynamic therapy (PDT) in neovascular age-related macular degeneration (AMD). Materials and Methods: This was a prospective study that involved treatment of naive eyes with neovascular AMD. The eyes were divided into 2 groups: the 1st group received only IVB and the 2nd group received IVB+PDT. An activity score (AS) was given to each lesion during all visits. Student’s t test and chi-square test were used for the comparison of parameters.Results: A total of 53 eyes were involved in the study. Mean follow-up time was 12.3 months. There was no significant difference with respect to lesion type, visual acuity, or central foveal thickness between the groups before treatment. After treatment AS decreased significantly in the two groups (p<0.05). Visual acuity was the same or increased in 92.5% of the eyes in group 1 and in 88.5% of the eyes in group 2 (p>0.05). The mean number of IVB/eye was 2.7 in group 1 and 2.6 in group 2 (p>0.05).Conclusion: IVB+PDT combination therapy seems not to be superior to IVB monotherapy with respect to visual acuity or retreatment needs in neovascular AMD. An activity scoring-guided strategy may help to determine the need for retreatments.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- 1. NG EW, Adamis AP.: Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368.
- 2. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351:2805-2816.
- 3. Ruckman J, Green LS, Beeson J, et al.: 2’-Fluoropyrimidine RNAbased aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20556-20567.
- 4. Rosenfeld PJ, Brown DM, Heier JS, et al.: Marina Study Group. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1419-1431.
- 5. Brown DM, Kaiser PK, Michels M, et al.: Anchor Study Group. Ranibizumab versus Verteporfin for neovascular agerelated macular degeneration. N Eng J Med. 2006;355:1432-1444.
- 6. Regillo CD, Brown DM, Abraham P, et al.: Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
- 7. Antoszyk AN, Tuomi L, Chung CY, et al.: FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145:862-874.
- 8. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
- 9. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
- 10. Rich RM, Rosenfeld PJ, Puliafito CA, et al.: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina. 2006;26:495-511.
- 11. Spaide RF, Laud K, Fine HF, et al.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
- 12. Yoganathan P, Deramo VA, Lai JC, et al.: Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006;26:994-998.
- 13. Lazic R, Gabric N.: Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:68-73.
- 14. Abrahám-Marin ML, Cortés-Luna CF, Alvarez-Rivera G, et al.: Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2007;245:651-655.
- 15. Aisenbrey S, Ziemssen F, Völker M, et al.: Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:941-948.
- 16. Chen CY, Wong TY, Heriot WJ.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol. 2007;143:510-512.
- 17. Bashshur ZF, Haddad ZA, Schakal A, et al.: Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256.
- 18. Melamud A, Stinnett S, Fekrat S.: Treatment of neovascular agerelated macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol. 2008;146:91-95.
- 19. Algvere PV, Steén B, Seregard S, et al.: A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 2008;86:482-489.
- 20. Arias L, Caminal JM, Casas L, et al.: A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol. 2008;92:1636-1641.
- 21. Dhalla MS, Shah GK, Blinder KJ, et al.: Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988-993.
- 22. Lazic R, Gabric N.: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179-1185.
- 23. Smith BT, Dhalla MS, Shah GK, et al.: Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2008;28:675-681.
- 24. Ladewig MS, Karl SE, Hamelman V, et al.: Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008;246:17-25.
- 25. Weber M, Cohen SY, Tadayoni R, et al.: Evolving intravitreous injection technique. J Fr Ophthalmol. 2008;31:625-629.
- 26. Verteporfin Roundtable Participants.: Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-134.
- 27. Ozdek S, Hondur A, Gurelik G, et al.: Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol. 2005;26:127-133.
- 28. Ozdek S.: My way of assessment of neovascular AMD activity. When to treat? When to stop? Ophthalmol Times Europe, May 2009.
- 29. Özdek Ş, Şekeryapan B, Ekici F, ve ark.: Patolojik miyopiye bağlı koroidal neovaskülarizasyonda kombinasyon tedavisi. Ret-Vit. 2010;18:197-202.
- 30. Haritoglou C, Kook D, Neubauer A, et al.: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005.
- 31. Iturralde D, Spaide RF, Meyerle CB, et al.: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284.
- 32. Travassos A, Teixeira S, Ferreira P, et al.: Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233-237.
| APA | ŞEKERYAPAN GEDİZ B, ÖZDEK Ş, Ozmen M, GURELIK G, HASANREİSOĞLU B (2011). Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. , 97 - 102. |
| Chicago | ŞEKERYAPAN GEDİZ BERRAK,ÖZDEK Şengül,Ozmen Mehmet,GURELIK GOKHAN,HASANREİSOĞLU Berati Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. (2011): 97 - 102. |
| MLA | ŞEKERYAPAN GEDİZ BERRAK,ÖZDEK Şengül,Ozmen Mehmet,GURELIK GOKHAN,HASANREİSOĞLU Berati Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. , 2011, ss.97 - 102. |
| AMA | ŞEKERYAPAN GEDİZ B,ÖZDEK Ş,Ozmen M,GURELIK G,HASANREİSOĞLU B Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. . 2011; 97 - 102. |
| Vancouver | ŞEKERYAPAN GEDİZ B,ÖZDEK Ş,Ozmen M,GURELIK G,HASANREİSOĞLU B Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. . 2011; 97 - 102. |
| IEEE | ŞEKERYAPAN GEDİZ B,ÖZDEK Ş,Ozmen M,GURELIK G,HASANREİSOĞLU B "Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results." , ss.97 - 102, 2011. |
| ISNAD | ŞEKERYAPAN GEDİZ, BERRAK vd. "Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results". (2011), 97-102. |
| APA | ŞEKERYAPAN GEDİZ B, ÖZDEK Ş, Ozmen M, GURELIK G, HASANREİSOĞLU B (2011). Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. Retina-Vitreus, 19(2), 97 - 102. |
| Chicago | ŞEKERYAPAN GEDİZ BERRAK,ÖZDEK Şengül,Ozmen Mehmet,GURELIK GOKHAN,HASANREİSOĞLU Berati Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. Retina-Vitreus 19, no.2 (2011): 97 - 102. |
| MLA | ŞEKERYAPAN GEDİZ BERRAK,ÖZDEK Şengül,Ozmen Mehmet,GURELIK GOKHAN,HASANREİSOĞLU Berati Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. Retina-Vitreus, vol.19, no.2, 2011, ss.97 - 102. |
| AMA | ŞEKERYAPAN GEDİZ B,ÖZDEK Ş,Ozmen M,GURELIK G,HASANREİSOĞLU B Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. Retina-Vitreus. 2011; 19(2): 97 - 102. |
| Vancouver | ŞEKERYAPAN GEDİZ B,ÖZDEK Ş,Ozmen M,GURELIK G,HASANREİSOĞLU B Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results. Retina-Vitreus. 2011; 19(2): 97 - 102. |
| IEEE | ŞEKERYAPAN GEDİZ B,ÖZDEK Ş,Ozmen M,GURELIK G,HASANREİSOĞLU B "Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results." Retina-Vitreus, 19, ss.97 - 102, 2011. |
| ISNAD | ŞEKERYAPAN GEDİZ, BERRAK vd. "Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results". Retina-Vitreus 19/2 (2011), 97-102. |
